390 related articles for article (PubMed ID: 14571839)
1. [Dendritic cell therapy for malignant glioma].
Yamanaka R; Homma J; Yajima N; Tsuchiya N; Tanaka R
No To Shinkei; 2003 Sep; 55(9):771-80. PubMed ID: 14571839
[TBL] [Abstract][Full Text] [Related]
2. Dendritic cell-based glioma immunotherapy (review).
Yamanaka R; Yajima N; Abe T; Tsuchiya N; Homma J; Narita M; Takahashi M; Tanaka R
Int J Oncol; 2003 Jul; 23(1):5-15. PubMed ID: 12792771
[TBL] [Abstract][Full Text] [Related]
3. [Peptide vaccination therapy for malignant glioma].
Yamanaka R; Itoh K
Brain Nerve; 2007 Mar; 59(3):251-61. PubMed ID: 17370651
[TBL] [Abstract][Full Text] [Related]
4. Novel immunotherapeutic approaches to glioma.
Yamanaka R
Curr Opin Mol Ther; 2006 Feb; 8(1):46-51. PubMed ID: 16506525
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell vaccines.
Yamanaka R; Kajiwara K
Adv Exp Med Biol; 2012; 746():187-200. PubMed ID: 22639169
[TBL] [Abstract][Full Text] [Related]
6. Cell- and peptide-based immunotherapeutic approaches for glioma.
Yamanaka R
Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cell vaccination in patients with malignant gliomas: current status and future directions.
de Vleeschouwer S; Rapp M; Sorg RV; Steiger HJ; Stummer W; van Gool S; Sabel M
Neurosurgery; 2006 Nov; 59(5):988-99; discussioin 999-1000. PubMed ID: 17143233
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell-based immunotherapy for malignant gliomas.
Akasaki Y; Black KL; Yu JS
Expert Rev Neurother; 2005 Jul; 5(4):497-508. PubMed ID: 16026233
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.
Yamanaka R; Homma J; Yajima N; Tsuchiya N; Sano M; Kobayashi T; Yoshida S; Abe T; Narita M; Takahashi M; Tanaka R
Clin Cancer Res; 2005 Jun; 11(11):4160-7. PubMed ID: 15930352
[TBL] [Abstract][Full Text] [Related]
10. Dendritic-cell- and peptide-based vaccination strategies for glioma.
Yamanaka R
Neurosurg Rev; 2009 Jul; 32(3):265-73; discussion 273. PubMed ID: 19214609
[TBL] [Abstract][Full Text] [Related]
11. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response.
Tsugawa T; Kuwashima N; Sato H; Fellows-Mayle WK; Dusak JE; Okada K; Papworth GD; Watkins SC; Gambotto A; Yoshida J; Pollack IF; Okada H
Gene Ther; 2004 Nov; 11(21):1551-8. PubMed ID: 15343358
[TBL] [Abstract][Full Text] [Related]
12. [Cellular immunotherapy for malignant glioma].
Okamoto Y; Yamashita J
Nihon Rinsho; 2005 Sep; 63 Suppl 9():557-62. PubMed ID: 16201581
[No Abstract] [Full Text] [Related]
13. Galectin-1 and immunotherapy for brain cancer.
Verschuere T; De Vleeschouwer S; Lefranc F; Kiss R; Van Gool SW
Expert Rev Neurother; 2011 Apr; 11(4):533-43. PubMed ID: 21469926
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of malignant glioma to chemotherapy through dendritic cell vaccination.
Liu G; Black KL; Yu JS
Expert Rev Vaccines; 2006 Apr; 5(2):233-47. PubMed ID: 16608423
[TBL] [Abstract][Full Text] [Related]
15. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC
Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624
[TBL] [Abstract][Full Text] [Related]
16. Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model.
Jouanneau E; Poujol D; Gulia S; Le Mercier I; Blay JY; Belin MF; Puisieux I
Cancer Immunol Immunother; 2006 Mar; 55(3):254-67. PubMed ID: 16133115
[TBL] [Abstract][Full Text] [Related]
17. T cell adoptive immunotherapy of newly diagnosed gliomas.
Plautz GE; Miller DW; Barnett GH; Stevens GH; Maffett S; Kim J; Cohen PA; Shu S
Clin Cancer Res; 2000 Jun; 6(6):2209-18. PubMed ID: 10873070
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic activity of ex-vivo generated IFNα-induced monocyte-derived dendritic cells in brain glioma patients.
Tyrinova TV; Leplina OY; Mishinov SV; Tikhonova MA; Shevela EY; Stupak VV; Pendyurin IV; Shilov AG; Alyamkina EA; Rubtsova NV; Bogachev SS; Ostanin AA; Chernykh ER
Cell Immunol; 2013; 284(1-2):146-53. PubMed ID: 23973877
[TBL] [Abstract][Full Text] [Related]
19. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells.
Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805
[TBL] [Abstract][Full Text] [Related]
20. Generation of a human leukocyte antigen-A24-restricted antitumor cell with the use of SART-1 peptide and dendritic cells in patients with malignant brain tumors.
Yoshida S; Tanaka R
J Lab Clin Med; 2004 Oct; 144(4):201-7. PubMed ID: 15514588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
